NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”) (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets protein-based biosurgery and passive immunotherapy products, announced today that the Company was added to the Russell 3000 and Russell 2000 Indexes when Russell Investment Group reconstituted its comprehensive set of U.S. and global equity indexes effective at the close of U.S. markets on June 22, 2007.
